Modified G-protein coupled receptors
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to modified G-protein coupled receptors (GPCRs). The modified GPCRs of the present invention include GPCRs that have been modified to have carboxyl terminal tails comprising one or more sites of phosphorylation, preferably one or more clusters of phosphorylation sites. The modified GPCRs of the present invention may comprise a retained portion of a carboxyl-terminus region from a first GPCR fused to a polypeptide, wherein the polypeptide comprises the one or more clusters of phosphorylation. The present invention also relates to methods of screening compounds and sample solutions for GPCR activity using the modified GPCRS.
34 Citations
37 Claims
-
1-30. -30. (canceled)
-
31. A method of screening compounds for GPCR activity comprising the steps of:
-
(a) providing a cell that expresses at least one GPCR comprising an amino acid sequence of a first GPCR modified by substitution of a carboxyl terminal tail portion of the first GPCR with a carboxyl terminal tail portion from a different GPCR, the substitution located downstream of an NPXXY (SEQ ID NO;
82) motif of the first GPCR, wherein the carboxyl terminal tail portion of the different GPCR comprises one or more clusters of phosphorylation sites and wherein the GPCR further comprises a putative site of palmitoylation 10 to 25 amino acid residues downstream of the NPXXY motif (SEQ. ID NO.;
82)wherein said cell further comprises arrestin conjugated to a detectable molecule;
(b) exposing the cell to the compound;
(c) detecting location of the arrestin within the cell;
(d) comparing the location of the arrestin within the cell in the presence of the compound to the location of the arrestin within the cell in the absence of the compound; and
(e) correlating a difference between (1) the location of the arrestin within the cell in the presence of the compound and (2) the presence of the location of the arrestin within the cell in the absence of the compound. - View Dependent Claims (32)
-
-
33-35. -35. (canceled)
-
36. A method of preventing and/or treating a disease associated with GPCR in mammals, comprising administering to a mammal an amount of an isolated nucleic acid sufficient to reduce or alleviate symptoms of said disease.
the isolated nucleic acid encoding a GPCR, wherein the GPCR comprises an amino acid sequence of a first GPCR modified by substitution of a carboxyl terminal tail portion of the first GPCR with a carboxyl terminal tail portion from a different GPCR, the substitution located downstream of an NPXXY (SEQ ID NO: - 82) motif of the first GPCR, wherein the carboxyl terminal tail portion of the different GPCR comprises one or more clusters of phosphorylation sites, and
wherein the GPCR further comprises a putative site of palmitoylation 10 to 25 amino acid residues downstream of the NPXXY motif (SEQ. ID NO.;
82).
- 82) motif of the first GPCR, wherein the carboxyl terminal tail portion of the different GPCR comprises one or more clusters of phosphorylation sites, and
-
37. A kit for identifying a molecule that modulates the activity of a GPCR, comprising a cell that expresses at least one GPCR comprising an amino acid sequence of a first GPCR modified by substitution of a carboxyl terminal tail portion of the first GPCR with a carboxyl terminal tail portion from a different GPCR, the substitution located downstream of an NPXXY (SEQ ID NO:
- 82) motif of the first GPCR, wherein the carboxyl terminal tail portion of the different GPCR comprises one or more clusters of phosphorylation sites, and wherein the GPCR further comprises a putative site of palmitoylation 10 to 25 amino acid residues downstream of the NPXXY motif (SEQ. ID NO.;
82),wherein said cell further comprises arrestin conjugated to a detectable molecule.
- 82) motif of the first GPCR, wherein the carboxyl terminal tail portion of the different GPCR comprises one or more clusters of phosphorylation sites, and wherein the GPCR further comprises a putative site of palmitoylation 10 to 25 amino acid residues downstream of the NPXXY motif (SEQ. ID NO.;
Specification